|
1
|
Goldhirsch A, Winer EP, Coates AS, Gelber
RD, Piccart-Gebhart M, Thürlimann B and Senn HJ; Panel members, .
Personalizing the treatment of women with early breast cancer:
Highlights of the st gallen international expert consensus on the
primary therapy of early breast cancer 2013. Ann Oncol.
24:2206–2223. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Arima N, Nishimura R, Osako T, Nishiyama
Y, Fujisue M, Okumura Y, Nakano M, Tashima R and Toyozumi Y: A
Comparison of the hot Spot and the average cancer cell counting
methods and the optimal cutoff point of the Ki-67 index for luminal
type breast cancer. Oncology. 90:43–50. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tashima R, Nishimura R, Osako T, Nishiyama
Y, Okumura Y, Nakano M, Fujisue M, Toyozumi Y and Arima N:
Evaluation of an optimal cut-off point for the Ki-67 index as a
prognostic factor in primary breast cancer: A retrospective study.
PLoS One. 10:e01195652015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bustreo S, Osella-Abate S, Cassoni P,
Donadio M, Airoldi M, Pedani F, Papotti M, Sapino A and Castellano
I: Optimal Ki67 cut-off for luminal breast cancer prognostic
evaluation: A large case series study with a long-term follow-up.
Breast Cancer Res Treat. 157:363–371. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Prat A, Cheang MC, Martín M, Parker JS,
Carrasco E, Caballero R, Tyldesley S, Gelmon K, Bemard PS, Nielsen
TO and Perou CM: Prognostic significance of progesterone
receptor-positive tumor cells within immunohistochemically defined
luminal A breast cancer. J Clin Oncol. 31:203–209. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tashima R, Nishimura Y, Arima N, Fujisue
M, Nakano M, Okumura Y, Osako T and Toyozumi Y: P260 Evaluation of
PgR expression as a prognostic factor in luminal HER2-negative
breast cancer. The Breast. 24 Suppl 1:S1162015. View Article : Google Scholar
|
|
7
|
O'Brien KM, Cole SR, Tse CK, Perou CM,
Carey LA, Foulkes WD, Dressler LG, Geradts J and Millikan RC:
Intrinsic breast tumor subtypes, race, and long-term survival in
the Carolina breast cancer study. Clin Cancer Res. 16:6100–6110.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sorlie T, Tibshirani R, Parker J, Hastie
T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et
al: Repeated observation of breast tumor subtypes in independent
gene expression data sets. Proc Natl Acad Sci USA. 100:8418–8423.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brenton JD, Carey LA, Ahmed AA and Caldas
C: Molecular classification and molecular forecasting of breast
cancer: Ready for clinical application? J Clin Oncol. 23:7350–7360.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Paik S, Shak S, Tang G, Kim C, Baker J,
Cronin M, Baehner FL, Walker MG, Watson D, Park T, et al: A
multigene assay to predict recurrence of tamoxifen-treated,
node-negative breast cancer. N Engl J Med. 351:2817–2826. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gianni L, Zambetti M, Clark K, Baker J,
Cronin M, Wu J, Mariani G, Rodriguez J, Carcangiu M, Watson D, et
al: Gene expression profiles in paraffin-embedded core biopsy
tissue predict response to chemotherapy in women with locally
advanced breast cancer. J Clin Oncol. 23:7265–7277. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Barcenas CH, Raghavendra A, Sinha AK, Syed
MP, Hsu L, Patangan MG Jr, Chavez-MacGregor M, Shen Y, Hortobagyi
GH, Valero V, et al: Outcomes in patients with early-stage breast
cancer who underwent a 21-gene expression assay. Cancer.
123:2422–2431. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kai K, Nishimura R, Arima N, Miyayama H
and Iwase H: p53 expression status is a significant molecular
marker in predicting the time to endocrine therapy failure in
recurrent breast cancer: A cohort study. Int J Clin Oncol.
11:426–433. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Voduc KD, Cheang MC, Tyldesley S, Gelmon
K, Nielsen TO and Kennecke H: Breast cancer subtypes and the risk
of local and regional relapse. J Clin Oncol. 28:1684–1691. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Arvold ND, Taghian AG, Niemierko A, Abi
Raad RF, Sreedhara M, Nguyen PL, Bellon JR, Wong JS, Smith BL and
Harris JR: Age, breast cancer subtype approximation, and local
recurrence after breast-conserving therapy. J Clin Oncol.
29:3885–3891. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Metzger-Filho O, Sun Z, Viale G, Price KN,
Crivellari D, Snyder RD, Gelber RD, Castiglione-Gertsch M, Coates
AS, Goldhirsch A and Cardoso F: Patterns of recurrence and outcome
according to breast cancer subtypes in lymph node-negative disease:
Results from international breast cancer study group trials VIII
and IX. J Clin Oncol. 31:3083–3090. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
McGuire A, Lowery AJ, Kell MR, Kerin MJ
and Sweeney KJ: Locoregional recurrence following breast cancer
surgery in the trastuzumab era: A systematic review by subtype. Ann
Surg Oncol. 24:3124–3132. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Harris L, Fritsche H, Mennel R, Norton L,
Ravdin P, Taube S, Somerfield MR, Hayes DF and Bast RC Jr; American
Society of Clinical Oncology, . American Society of Clinical
Oncology 2007 update of recommendations for the use of tumor
markers in breast cancer. J Clin Oncol. 25:5287–5312. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
National Comprehensive Cancer Network
(NCCN) guidelines, Breast Cancer Version 2.2011. http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
|
|
20
|
Paik S, Tang G, Shak S, Kim C, Baker J,
Kim W, Cronin M, Baehner FL, Watson D, Bryant J, et al: Gene
expression and benefit of chemotherapy in women with node-negative,
estrogen receptor-positive breast cancer. J Clin Oncol.
24:3726–3734. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Albain KS, Barlow WE, Shak S, Hortobagyi
GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL,
Davidson NE, et al: Prognostic and predictive value of the 21-gene
recurrence score assay in postmenopausal women with node-positive,
oestrogen-receptor-positive breast cancer on chemotherapy: A
retrospective analysis of a randomised trial. Lancet Oncol.
11:55–65. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nishimura R, Osako T, Okumura Y, Hayashi
M, Toyozumi Y and Arima N: Ki-67 as a prognostic marker according
to breast cancer subtype and a predictor of recurrence time in
primary breast cancer. Exp Ther Med. 1:747–754. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Inwald EC, Klinkhammer-Schalke M,
Hofstädter F, Zeman F, Koller M, Gerstenhauer M and Ortmann O:
Ki-67 is a prognostic parameter in breast cancer patients: Results
of a large population-based cohort of a cancer registry. Breast
Cancer Res Treat. 139:539–552. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fasching PA, Heusinger K, Haeberle L,
Niklos M, Hein A, Bayer CM, Rauh C, Schulz-Wendtland R, Bani MR,
Schrauder M, et al: Ki67, chemotherapy response, and prognosis in
breast cancer patients receiving neoadjuvant treatment. BMC Cancer.
11:4862011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bae SY, Kim S, Lee JH, Lee HC, Lee SK, Kil
WH, Kim SW, Lee JE and Nam SJ: Poor prognosis of single hormone
receptor-positive breast cancer: Similar outcome as triple-negative
breast cancer. BMC Cancer. 15:1382015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Viale G, Regan MM, Maiorano E,
Mastropasqua MG, Golouh R, Penin T, Brown RW, Kovács A, Pillay K,
Ohlschlegel C, et al: Chemoendocrine compared with endocrine
adjuvant therapies for node-negative breast cancer: Predictive
value of centrally reviewed expression of estrogen and progesterone
receptors-An International Breast Cancer Study Group. J Clin Oncol.
26:1404–1410. 2008. View Article : Google Scholar : PubMed/NCBI
|
